Results 11 to 20 of about 182,022 (327)

Serum IgG antibodies to Shigella lipopolysaccharide antigens – a correlate of protection against shigellosis

Human Vaccines & Immunotherapeutics, 2019
Shigella is a leading cause of diarrhea among children globally and of diarrheal deaths among children under 5 years of age in low- and middle-income countries. To date, no licensed Shigella vaccine exists. We review evidence that serum IgG antibodies to
Dani Cohen, Shiri Meron-Sudai, Anya Bialik, Valeria Asato, Sophy Goren, Ortal Ariel-Cohen, Arava Reizis, Amit Hochberg, Shai Ashkenazi   +8 more
doaj   +2 more sources

Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human

Human Vaccines & Immunotherapeutics, 2019
Shigella are gram-negative bacteria that cause severe diarrhea and dysentery, with a high level of antimicrobial resistance. Disease-induced protection against reinfection in Shigella-endemic areas provides convincing evidence on the feasibility of a ...
Louis-Antoine Barel, Laurence A. Mulard
doaj   +2 more sources

Molecular Mechanisms of Shigella Pathogenesis; Recent Advances

International Journal of Molecular Sciences, 2023
Shigella species are the main cause of bacillary diarrhoea or shigellosis in humans. These organisms are the inhabitants of the human intestinal tract; however, they are one of the main concerns in public health in both developed and developing countries.
B. Pakbin, W. Brück, T. Brück
semanticscholar   +1 more source

Rapid discrimination of Shigella spp. and Escherichia coli via label-free surface enhanced Raman spectroscopy coupled with machine learning algorithms

Frontiers in Microbiology, 2023
Shigella and enterotoxigenic Escherichia coli (ETEC) are major bacterial pathogens of diarrheal disease that is the second leading cause of childhood mortality globally. Currently, it is well known that Shigella spp., and E. coli are very closely related
W. Liu, Jia-Wei Tang, Jing-Yi Mou, Jingqiao Lyu, Yu-Wei Di, Yaoping Liao, Yan-fei Luo, Zheng Li, Xiang Wu, Liang Wang   +9 more
semanticscholar   +1 more source

Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study

Clinical Infectious Diseases, 2023
Background We evaluated the burden of Shigella spp from children aged 0–59 months with medically attended moderate-to-severe diarrhea and matched controls at sites in Mali, The Gambia, and Kenya participating in the Vaccine Impact on Diarrhea in Africa ...
I. Kasumba, H. Badji, H. Powell, M. J. Hossain, R. Omore, S. Sow, J. Verani, J. Platts-Mills, John Marc Widdowson, Syed M. A. Zaman, Jennifer A. Jones, S. Sen, Jasnehta Permala-Booth, S. Nasrin, Anna Roose, Dilruba Nasrin, J. B. Ochieng, J. Juma, Sanogo Doh, J. C. Jones, M. Antonio, A. Awuor, Ciara E Sugerman, Nora L. Watson, Christopher Focht, Jieng-Lung Liu, E. Houpt, K. Kotloff, S. Tennant   +28 more
semanticscholar   +1 more source

Toward a Shigella Vaccine: Opportunities and Challenges to Fight an Antimicrobial-Resistant Pathogen

International Journal of Molecular Sciences, 2023
Shigellosis causes more than 200,000 deaths worldwide and most of this burden falls on Low- and Middle-Income Countries (LMICs), with a particular incidence in children under 5 years of age.
M. M. Raso, V. Arato, G. Gasperini, F. Micoli   +3 more
semanticscholar   +1 more source

Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy

Journal of the American Society of Nephrology, 2022
Significance Statement Gut dysbiosis contributes to dysfunctional mucosal immunity, which may lead to production of nephrotoxic immune complexes specific to IgA nephropathy (IgAN).
Jin Zhao, M. Bai, Xiaoxuan Ning, Yunlong Qin, Yuwei Wang, Zixian Yu, Ruijuan Dong, Yumeng Zhang, Shiren Sun   +8 more
semanticscholar   +1 more source

The Shigella Vaccines Pipeline

Vaccines, 2022
Shigella is the leading cause of global diarrheal deaths that currently lacks a licensed vaccine. Shigellosis drives antimicrobial resistance and leads to economic impact through linear growth faltering.
C. MacLennan, Stephanie Grow, Lyou-fu Ma, A. Steele   +3 more
semanticscholar   +1 more source

Towards a Four-Component GMMA-Based Vaccine against Shigella

Vaccines, 2022
Shigellosis remains a major public health problem around the world; it is one of the leading causes of diarrhoeal disease in low- and middle-income countries, particularly in young children.
F. Micoli, U. Nakakana, F. Berlanda Scorza   +2 more
semanticscholar   +1 more source

Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs

Nature Microbiology, 2022
Shigella spp. are the leading bacterial cause of severe childhood diarrhoea in low- and middle-income countries (LMICs), are increasingly antimicrobial resistant and have no widely available licenced vaccine.
Rebecca J. Bengtsson, A. Simpkin, Caisey V. Pulford, Ross Low, D. Rasko, D. Rigden, N. Hall, E. Barry, S. Tennant, K. Baker   +9 more
semanticscholar   +1 more source